Literature DB >> 22634360

Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex.

James Bogenpohl1, Adriana Galvan, Xing Hu, Thomas Wichmann, Yoland Smith.   

Abstract

Group III metabotropic glutamate receptors (mGluR4,7,8) are widely distributed in the basal ganglia. Injection of group III mGluR agonists into the striatopallidal complex alleviates parkinsonian symptoms in 6-hydroxydopamine-treated rats. In vitro rodent studies have suggested that this may be partly due to modulation of synaptic transmission at striatopallidal and corticostriatal synapses through mGluR4 activation. However, the in vivo electrophysiological effects of group III mGluRs activation upon basal ganglia neurons activity in nonhuman primates remain unknown. Thus, in order to examine the anatomical substrates and physiological effects of group III mGluRs activation upon striatal and pallidal neurons in monkeys, we used electron microscopy immunohistochemistry to localize mGluR4, combined with local administration of the group III mGluR agonist L-AP4, or the mGluR4 positive allosteric modulator VU0155041, to assess the effects of group III mGluR activation on the firing rate and pattern of striatal and pallidal neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated parkinsonian monkeys. At the ultrastructural level, striatal mGluR4 immunoreactivity was localized in pre- (60%) and post-synaptic (30%) elements, while in the GPe, mGluR4 was mainly expressed pre-synaptically (90%). In the putamen, terminals expressing mGluR4 were evenly split between putative excitatory and inhibitory terminals, while in the GPe, most labeled terminals displayed the ultrastructural features of striatal-like inhibitory terminals, though putative excitatory boutons were also labeled. No significant difference was found between normal and parkinsonian monkeys. Extracellular recordings in awake MPTP-treated monkeys revealed that local microinjections of small volumes of L-AP4 resulted in increased firing rates in one half of striatal cells and one third of pallidal cells, while a significant number of neurons in both structures showed either opposite effects, or did not display any significant rate changes following L-AP4 application. VU0155041 administration had little effect on firing rates. Both compounds also had subtle effects on bursting and oscillatory properties, acting to increase the irregularity of firing. The occurrence of pauses in firing was reduced in the majority (80%) of GPe neurons after L-AP4 injection. Our findings indicate that glutamate can mediate multifarious physiological effects upon striatal and pallidal neurons through activation of pre-synaptic group III mGluRs at inhibitory and excitatory synapses in parkinsonian monkeys. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22634360      PMCID: PMC3490034          DOI: 10.1016/j.neuropharm.2012.05.017

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  57 in total

1.  A network representation of response probability in the striatum.

Authors:  Pablo M Blazquez; Naotaka Fujii; Jun Kojima; Ann M Graybiel
Journal:  Neuron       Date:  2002-03-14       Impact factor: 17.173

2.  Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse.

Authors:  Ornella Valenti; Michael J Marino; Marion Wittmann; Edward Lis; Anthony G DiLella; Gene G Kinney; P Jeffrey Conn
Journal:  J Neurosci       Date:  2003-08-06       Impact factor: 6.167

3.  Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats.

Authors:  Nathalie Breysse; Marianne Amalric; Pascal Salin
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

Review 4.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

5.  Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS.

Authors:  C Corti; L Aldegheri; P Somogyi; F Ferraguti
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

6.  Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates.

Authors:  T Wichmann; M A Kliem; M R DeLong
Journal:  Exp Neurol       Date:  2001-02       Impact factor: 5.330

7.  Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment.

Authors:  Michael J Marino; David L Williams; Julie A O'Brien; Ornella Valenti; Terrence P McDonald; Michelle K Clements; Ruiping Wang; Anthony G DiLella; J Fred Hess; Gene G Kinney; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-30       Impact factor: 11.205

Review 8.  Striatal glutamatergic mechanisms and extrapyramidal movement disorders.

Authors:  Thomas N Chase; Francesco Bibbiani; Justin D Oh
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.

Authors:  Paolo Gubellini; Barbara Picconi; Monica Bari; Natalia Battista; Paolo Calabresi; Diego Centonze; Giorgio Bernardi; Alessandro Finazzi-Agrò; Mauro Maccarrone
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

10.  Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus.

Authors:  T Matsui; H Kita
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

View more
  20 in total

1.  The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia.

Authors:  Ranjani Ponnazhagan; Ashley S Harms; Aaron D Thome; Asta Jurkuvenaite; Rocco Gogliotti; Colleen M Niswender; P Jeffrey Conn; David G Standaert
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

Review 2.  The external globus pallidus: progress and perspectives.

Authors:  Daniel J Hegeman; Ellie S Hong; Vivian M Hernández; C Savio Chan
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

3.  Localization and function of dopamine receptors in the subthalamic nucleus of normal and parkinsonian monkeys.

Authors:  Adriana Galvan; Xing Hu; Karen S Rommelfanger; Jean-Francois Pare; Zafar U Khan; Yoland Smith; Thomas Wichmann
Journal:  J Neurophysiol       Date:  2014-04-23       Impact factor: 2.714

4.  Reduced cortical innervation of the subthalamic nucleus in MPTP-treated parkinsonian monkeys.

Authors:  Abraham Mathai; Yuxian Ma; Jean-Francois Paré; Rosa M Villalba; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2015-02-12       Impact factor: 13.501

5.  Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.

Authors:  Hanna Iderberg; Natallia Maslava; Analisa D Thompson; Michael Bubser; Colleen M Niswender; Corey R Hopkins; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones; M Angela Cenci
Journal:  Neuropharmacology       Date:  2015-03-04       Impact factor: 5.250

Review 6.  Development of allosteric modulators of GPCRs for treatment of CNS disorders.

Authors:  Hilary Highfield Nickols; P Jeffrey Conn
Journal:  Neurobiol Dis       Date:  2013-09-27       Impact factor: 5.996

7.  Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.

Authors:  Colleen M Niswender; Carrie K Jones; Xin Lin; Michael Bubser; Analisa Thompson Gray; Anna L Blobaum; Darren W Engers; Alice L Rodriguez; Matthew T Loch; J Scott Daniels; Craig W Lindsley; Corey R Hopkins; Jonathan A Javitch; P Jeffrey Conn
Journal:  ACS Chem Neurosci       Date:  2016-08-05       Impact factor: 4.418

8.  Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease.

Authors:  R M Villalba; T Wichmann; Y Smith
Journal:  Brain Struct Funct       Date:  2013-03-19       Impact factor: 3.270

9.  Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications.

Authors:  Manuela Mellone; Fabrizio Gardoni
Journal:  J Neural Transm (Vienna)       Date:  2018-01-31       Impact factor: 3.575

Review 10.  Metabotropic glutamate receptors: targets for neuroprotective therapies in Parkinson disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  Curr Opin Pharmacol       Date:  2018-03-30       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.